To examine the effect of tofacitinib on the expression of TGFβRI during CD4+ T cell activation, naïve CD4+ T cells from patients with active SLE were treated with different concentrations of tofacitinib (0.1-10 μM) and anti-CD3/CD28 beads in culture. Here, CD4 is linked to systemic lupus erythematosus.